Linaclotide utilization and potential for off-label use and misuse in three European countries

Linaclotide utilization and potential for off-label use and misuse in three European countries

Introduction: Linaclotide is approved for adults with moderate-to-severe irritable bowel syndrome (IBS) with constipation (IBS-C). Linaclotide is not indicated for weight loss or for patients with inflammatory bowel disease (IBD); it is contraindicated in patients with mechanical bowel obstruction (...

Full description

Bibliographic Details
Main Authors: Javier Cid-Ruzafa, Brian E. Lacy, Anna Schultze, Mai Duong, Yi Lu, Mireia Raluy-Callado, Robert Donaldson, Darren Weissman, Ainhoa Gómez-Lumbreras, Dan Ouchi, Maria Giner-Soriano, Rosa Morros, Ahunna Ukah, Daniel Pohl
Format: Article
Language:English
Published: SAGE Publishing 2022-06-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/17562848221100946

Internet

https://doi.org/10.1177/17562848221100946

Similar Items